Physician profile
Terry Mark Roach
NPI 1831162585
$12,020.10
in general payments reported to CMS, 2019-2025
48 companies · $663 in 2025
The $663 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,282 · 2020: $1,790 · 2021: $1,259 · 2022: $4,508 · 2023: $1,038 · 2024: $481 · 2025: $663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,157 · Education: $25.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,156.87 |
| Education | $25.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,990.08 | 2019-2025 | Ubrelvy, Qulipta, Vraylar |
| Astrazeneca Pharmaceuticals LP | $1,314.44 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $906.64 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $754.92 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $535.88 | 2019-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $533.20 | 2019-2025 | |
| Amarin Pharma, INC. | $490.02 | 2019-2021 | |
| Glaxosmithkline, LLC. | $352.60 | 2019-2025 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $313.40 | 2019-2025 | Repatha, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $295.82 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $227.14 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $189.18 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $179.55 | 2019-2024 | Xarelto, Spravato |
| Allergan, INC. | $168.26 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $133.27 | 2019-2023 |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Terry Roach listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.